Skip to Content
Merck
  • Tolfenamic acid and migraine--aspects on prostaglandins and leukotrienes.

Tolfenamic acid and migraine--aspects on prostaglandins and leukotrienes.

Pharmacology & toxicology (1994-01-01)
H Vapaatalo
ABSTRACT

Migraine is a paroxysmal disorder characterized by recurrent attacks of headache, with or without associated visual and gastrointestinal disturbances. Migraine can be classified in two main groups, common and classic. Theories trying to explain the pathogenesis of a migraine attack may emphasize either the central or peripheral aspects of the disease. The vascular theory may stress the importance of either central or peripheral blood flow or both. Cerebral vasoconstriction in the early phases of the attack is followed by vasodilatation and pain. Biochemical mediators of vascular responses are not exactly known, but platelets and 5-hydroxytryptamine and thromboxane released from them as well as noradrenaline are potent vasoconstrictors, while kinins and prostaglandins can explain the vasodilatory phase of migraine attacks. This review presents evidence for the role of arachidonic acid metabolites, prostaglandins and leukotrienes in migraine. The evidence comes from the measurements of eicosanoids in biological fluids during and after the attack, infusion studies where vasodilatory prostaglandins mimic the migraneous symptoms, and the good effect of non-steroidal anti-inflammatory drugs in the treatment and prophylaxis of migraine attacks. Additional data are based on experimental biochemical studies in which catecholamines and indolamines have been shown to increase the synthesis of vasodilatory prostaglandins. However, the final evidence still awaits its confirmation.

MATERIALS
Product Number
Brand
Product Description

Tolfenamic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Tolfenamic acid, VETRANAL®, analytical standard
Sigma-Aldrich
Tolfenamic acid, NSAID